Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ) is now available.
Shanghai Henlius Biotech, Inc. announced that its subsidiary, Henlius Biologics, has received EU GMP certification for its production lines of HLX11 and HLX14, indicating compliance with European manufacturing standards. This certification enhances the company’s industry positioning by facilitating the global commercialization of its biosimilar products, potentially impacting stakeholders by expanding market access and increasing competitiveness in the pharmaceutical industry.
The most recent analyst rating on (HK:2696) stock is a Buy with a HK$61.98 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
More about Shanghai Henlius Biotech, Inc. Class H
Shanghai Henlius Biotech, Inc. is a biotechnology company based in China, focusing on the development and commercialization of biosimilar and innovative biologic products. The company specializes in monoclonal antibody injections, targeting areas such as oncology and osteoporosis, with a market focus on global commercialization excluding certain regions in China.
Average Trading Volume: 1,416,604
Technical Sentiment Signal: Buy
Current Market Cap: HK$28.7B
For an in-depth examination of 2696 stock, go to TipRanks’ Overview page.